Lyell Immunopharma (LYEL) Stock Price, Quote, News & History

Comments

Lyell Immunopharma Inc (LYEL) Stock Price, Quote, News & History

LYELNASDAQ

Trade with Public

$20.06

0.773.99%

At close: Mar 31, 5:00 PM EST

$20.06

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$19.62

Close

$20.06

Volume / Avg.

112.15K / 104.90K

Day Range

$19.53 - $20.67

52 Wk Range

7.65 - 45.00

Market Cap

$467.54M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

4.77%

Days to Cover

8.59

Recent Lyell Immunopharma Inc News

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Vandana Singh

Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-150.02M

Investing Cash Flow (TTM)

54.10M

Financing Cash Flow (TTM)

50.41M

Free Cash Flow (TTM)

-150.80M

Capital Expenditure (TTM)

-780.00K

Net Change in Cash (TTM)

-45.52M

Analyst Trends and Forecast

1

Nov 25

1

Dec 25

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$254.53M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

9182.74

PB Ratio (TTM)

1.82

Earnings Yield % (TTM)

-83.04%

Earnings Yield % (FWD)

-58.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.65

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$60.18M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$19.62

Close

$20.06

Volume / Avg.

112.15K / 104.90K

Day Range

$19.53 - $20.67

52 Wk Range

7.65 - 45.00

Market Cap

$467.54M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

4.77%

Days to Cover

8.59

About

Sector

Health Care

Industry

Biotechnology

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Lyell Immunopharma (LYEL) stock?

A

You can purchase shares of Lyell Immunopharma (NASDAQ:LYEL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Lyell Immunopharma (LYEL) competitors?

A

Other companies in Lyell Immunopharma’s space includes: 4D Molecular Therapeutics Inc (NASDAQ:FDMT), Upstream Bio Inc (NASDAQ:UPB), Larimar Therapeutics Inc (NASDAQ:LRMR), Prothena Corp PLC (NASDAQ:PRTA) and ADC Therapeutics SA (NYSE:ADCT).

Q

What is the forecast, or price target, for Lyell Immunopharma (LYEL) stock?

A

Lyell Immunopharma has a consensus price target of $19.17.

Q

What is the current price for Lyell Immunopharma (LYEL)?

A

The stock price for Lyell Immunopharma (NASDAQ: LYEL) is $20.06 last updated March 31, 2026 at 4:00 PM EDT.

Q

Does Lyell Immunopharma (LYEL) pay a dividend?

A

There are no upcoming dividends for Lyell Immunopharma.

Q

When is Lyell Immunopharma (NASDAQ:LYEL) reporting earnings?

A

Lyell Immunopharma does not have any upcoming earnings scheduled.

Q

Is Lyell Immunopharma (LYEL) going to split?

A

There is no upcoming split for Lyell Immunopharma.

Q

What sector and industry does Lyell Immunopharma (LYEL) operate in?

A

Lyell Immunopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

4D Molecular Therapeutics Inc

Larimar Therapeutics Inc

Kyverna Therapeutics Inc

NASDAQ:KYTX

$8.63

%

Eupraxia Pharmaceuticals Inc

NASDAQ:EPRX

$6.74

-6.91%

Key Statistics

Open

$19.62

Close

$20.06

Volume / Avg.

112.15K / 104.90K

Day Range

$19.53 - $20.67

52 Wk Range

7.65 - 45.00

Market Cap

$467.54M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

4.77%

Days to Cover

8.59

Recent Lyell Immunopharma Inc News

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Vandana Singh

Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-150.02M

Investing Cash Flow (TTM)

54.10M

Financing Cash Flow (TTM)

50.41M

Free Cash Flow (TTM)

-150.80M

Capital Expenditure (TTM)

-780.00K

Net Change in Cash (TTM)

-45.52M

Analyst Trends and Forecast

1

Nov 25

1

Dec 25

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$254.53M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

9182.74

PB Ratio (TTM)

1.82

Earnings Yield % (TTM)

-83.04%

Earnings Yield % (FWD)

-58.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.65

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$60.18M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$19.62

Close

$20.06

Volume / Avg.

112.15K / 104.90K

Day Range

$19.53 - $20.67

52 Wk Range

7.65 - 45.00

Market Cap

$467.54M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

4.77%

Days to Cover

8.59

About

Sector

Health Care

Industry

Biotechnology

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry